Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232804 | 0.79 | TAAR1 (0.46) | TAAR1PYCR1IDO1 | |
| SCHEMBL536198 | 0.78 | AOC3 (0.52) | LOXL2AOC3ALDH1A1 | |
| SCHEMBL6231688 | 0.76 | LOXL2 (0.50) | LOXL2IDO1NSD2 | |
| SCHEMBL8525708 | 0.75 | AOC3 (0.30) | AOC3 | |
| SCHEMBL5537402 | 0.75 | PYCR1 (0.47) | AOC3TAAR1ESR1ESR2PYCR1 | |
| SCHEMBL5542200 | 0.72 | KCNA5 (0.50) | KCNA5ALDH1A1 | |
| SCHEMBL15597723 | 0.71 | AOC3 (0.63) | LOXL2AOC3TAAR1ESR1ESR2 | |
| SCHEMBL22959010 | 0.71 | FFAR1 (0.39) | RIPK1BCL2A1 | |
| SCHEMBL17542506 | 0.71 | HDAC3 (0.47) | LOXL2AOC3ESR1ESR2RIPK1 | |
| SCHEMBL933733 | 0.70 | ESR1 (0.57) | LOXL2AOC3TAAR1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| CN-102656167-A | Hiv integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245241-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | LOXL2 4191/4885AOC3 4442/4885TAAR1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.